A key question for ESO-T01 and other in vivo candidates will be the durability of their cancer eradication. While the ...
Whatever the reasons, AstraZeneca has emerged as the first IL-33 player to show consistent efficacy. Sanofi and Regeneron ...
AstraZeneca showcases three new pioneering drugs at major cancer convention in Berlin. AstraZeneca is enjoying a banner year, averaging a successful phase-three readout every month. The chief ...
Pharma company AstraZeneca has publicly released preclinical data from more than 50 of its medicines in order to find new drug combinations for cancer treatments. The data AstraZeneca released will be ...
AstraZeneca said that its drugs Imfinzi and Imjudo, combined with lenvatinib and transarterial chemoembolisation or TACE, showed "clinically meaningful improvement" in progression-free survival rates ...
(Alliance News) - AstraZeneca PLC on Sunday said Imfinzi has been approved in the EU as the first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results